Side effects in relapsed CLL

Most common side effects in the ZYDELIG® trial in
relapsed CLL

The most common side effects seen in >20% of people with relapsed CLL taking ZYDELIG + Rituxan® (rituximab) and those taking placebo + Rituxan are shown in this table. These are not all the possible side effects of ZYDELIG.

Side effect
ZYDELIG
+ Rituxan
n=110
Placebo
+ Rituxan
n=108
Fever
40%
19%
Diarrhea
32%
19%
Pneumonia
30%
19%
Nausea
27%
23%
Chills
25%
16%
Rash
25%
6%
  • The most frequent serious side effects in clinical studies in combination with Rituxan were pneumonia (23%), diarrhea (10%), fever (9%), sepsis (8%), and fever with neutropenia (5%)
  • Serious side effects were reported in 59% of patients
View serious side effects

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also call 1-800-GILEAD-5 (1-800-445-3235).

Clip board with check mark icon

Tips for managing & reporting side effects

Side effects may occur when you take ZYDELIG. Some side effects may be managed if discussed early with your treatment team

Learn more
Address book icon

Patient & caregiver resources

Find downloadable resources to help you get and stay informed about your disease and treatment

Learn more

Reference:

  1. ZYDELIG® (idelalisib) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; rev January 2018.